June 5, 2017 / 8:22 PM / 2 months ago

BRIEF-CVT-301 phase 3 data showed significantly positive results

1 Min Read

June 5 (Reuters) - Acorda Therapeutics Inc

* CVT-301 phase 3 data showed significantly improved motor function during off periods in Parkinson’s disease

* Multiple secondary endpoints were supportive of primary endpoint result

* Acorda plans to file new drug application (NDA) in U.S. by end of Q2 2017

* CVT-301 phase 3 span-PD study met primary endpoint Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below